Biotin-Ahx-Nedd8-Dha

Biotin-Ahx-Nedd8-Dha

details

UbiQ-106 is a new and first of its kind activity based probe for Nedd8 E1, E2 and E3 ligases [Mulder et al. 2016]. It is based on the Nedd8 sequence in which the C-terminal Gly76 has been replaced by a dehydroalanine (Dha) residue. The N-terminus is labeled with biotin; an aminohexanoic acid (Ahx) linker is used to create extra space between the biotin and Nedd8 protein for efficient access of biotin binding entities. It has been prepared by total chemical synthesis and is therefore well-defined in terms of biotinylation site.

UbiQ-106 is processed in a native manner by E1, E2 and E3 ligases and during this process it forms an electrophilic intermediate that can react with the active site Cys residue of the E1, E2 and E3 enzyme, thereby creating a covalent bond (see figure).

Product Attachments

View FileUbiQ-106 Productsheet B01072015-001
crystallizationpull downpurificationwestern blotphenotypic protein profilingtarget inhibitor profiling

Qty Available: 0

€350.00
€350.00

Request product in bulk

mg
name Biotin-Ahx-Nedd8-Dha
product code UbiQ-106
Applications crystallization, pull down, purification, western blot, phenotypic protein profiling, target inhibitor profiling
target E1/E2/E3
source synthetic, human sequence
shipping lyophilized powder
purity ≥95% by RP-HPLC
molecular weight 8.93 kDa
storage Powder at −20°C; solution at −80°C. Protect from light. Please avoid multiple freeze/thaw cycles.
sample preparation For detailed sample preparation see product sheet.
regulatory statement For laboratory research use only, not for use in humans.
  • Triple E poster

     as presented by UbiQ on Keystone 2016

    download this pdf
  • Mulder, A., et al.

    Mulder, A., et al. A cascading activity-based probe sequentially targets E1–E2–E3 ubiquitin enzymes. Nat. Chem. Biol. 2016. 16 May Advance Online Publication

    DOI: 10.1038/NCHEMBIO.2084

  • TripleE_Probes factsheet download this pdf
  • UbiQ-Probes crystallization overview download this pdf
  • UbiQ's drug discovery expertise overview

     

    download this pdf